Washington Biotechnology
  • In Vivo CRO Services
    • Autoimmune & Inflammatory Diseases
      • Multiple Sclerosis
      • Gout
      • Inflammatory Bowel Disease (IBD)
      • Dermatitis (Contact)
      • Lupus
      • Nephritis
      • Pancreatitis
      • Hepatitis
      • Psoriasis
      • Pulmonary Fibrosis
      • Diabetes
      • General Inflammation Assessment
      • Acute Choleostasis Model
    • Rheumatoid Arthritis
      • Collagen-Induced Arthritis Model
      • Adjuvant-Induced Arthritis Model
      • Carrageenan Air Pouch Model
      • Zymosan Air Pouch Model
      • Pristane-Induced Arthritis Model
      • Ovalbumin-Induced Arthritis Model
      • SCW PG-PS 10S Rat Model
      • Arthritis Combo Testing: Rodent/Rabbit
    • Cancer
      • WBI Cell Lines for Cancer Models
      • Xenograft, Orthotopic & Syngeneic Models
    • Bacterial Infection
      • MRSA Model
      • Listeria Model
    • Pain Studies
      • Formalin Test (Chemical Sensitivity)
    • Pharmacokinetics and Toxicity
      • Pharmacokinetics (PK)
      • Toxicity and MTD Studies
    • Support Services
      • In Vitro Compound Screening for Anti-inflammatory Activity
    • WBI Project Management
  • About Us
  • What's New
  • Contact Us
  • Sitemap
  • Careers
  • In Vivo CRO Services
    • Autoimmune & Inflammatory Diseases
    • Rheumatoid Arthritis
    • Cancer
      • WBI Cell Lines for Cancer Models
      • Xenograft, Orthotopic & Syngeneic Models
        • Breast Cancer Models (BT-474 & MDA-MB-231)
        • Prostate Cancer Model (PC-3)
        • Lymphoma Model (Raji)
        • Melanoma Models (Syngeneic B16-F10 &, Xenograft A375)
        • Liver Cancer Models (MHCC97H, Huh-7)
        • Lung Cancer Model (H358)
        • Kidney Cancer Model (786-0)
        • Pancreatic Cancer Model (HPAFII)
        • Colon Cancer Model (HT-29)
        • Brain Cancer (Glioma) Model (U87 MG)
        • Myeloma Model (RPMI-8226)
        • Head and Neck Cancer Models (FaDu, A253)
    • Bacterial Infection
    • Pain Studies
    • Pharmacokinetics and Toxicity
    • Support Services
    • WBI Project Management
  • About Us
  • What's New
  • Contact Us
  • Sitemap
  • Careers

Xenograft, Orthotopic & Syngeneic Models

 

WBI offers xenograft, orthotopic and syngeneic models for assessment of anti-cancer agents.

 

Xenograft or Orthotopic Model
Species Athymic nude or SCID mouse; or Athymic nude rat
Group Size

5-20

Dosing
  • Oral
  • Intravenous
  • Intraperitoneal
  • Subcutaneous
  • Infusion
  • Intranasal
  • Intratracheal
Readouts Tumor volume
Optional Services
  • Validation of cell lines for tumor growth
  • MTD determinations (acute or multi-dose)
  • Tumor recoveries at termination; weights and preservation
  • Blood collection
  • PK
  • Organ recoveries & preservation
  • Histology
  • Metastasis observations
  • Custom development

 

 

Syngeneic Mouse Models
Manipulation of the immune response through administration of immune therapeutics is an active area of cancer treatments. To evaluate potential treatments, a functional immune system in test animals is essential and is available in syngeneic mouse models. Efficacy of test materials is rapidly evaluated within 2-3 weeks of cell implants and initial dosing with test material.
Cancer Type Cell Line Mouse Strain

Breast

4T1

Balb/c

Colorectal

CT26

MC38

Balb/c

C57BL/6

Melanoma

B16-F10

C57BL/6

Lung

Lewis Lung

C57BL/6

Pancreas Pan02 C57BL/6
 

Cell implantation

Subcutaneous, intravenous

Controls

Anti-PD-1 antibody

Anti-PD-L1 antibody

Anti-CTLA-4 antibody

Readouts

Tumor volumes measured and reported 3 times weekly with statistical analysis for efficacy.

Survival, lung metastasis.

Collections

Tumors at termination

Optional: Plasma (or serum) samples during tumor growth and/or at termination; organs (lymph node, spleen, etc.)

Dissociation, cryo-conservation and shipment of tumor cells, lymph node cells, spleen cells

Project scheduling

Start-up with cell implants within 2 weeks of order

Completion within 4 weeks of order.

Optional study extension: Re-implant of cancer cells for evaluation of memory T cells

 

 

 

The following are selected cancer models:

 

Breast Cancer Models (BT-474 & MDA-MB-231)

Prostate Cancer Model (PC-3)

Lymphoma Model (Raji)

Melanoma Models (Syngeneic B16-F10, A375, LOX 1MV1)

Liver Cancer Models (MHCC97H, Huh-7)

Lung Cancer Model (H358)

Kidney Cancer Model (786-0)

Pancreatic Cancer Model (HPAFII)

Colon Cancer Model (HT-29)

Brain Cancer (Glioma) Model (U87 MG)

Myeloma Model (RPMI-8226)

Head and Neck Cancer Models (FaDu, A253)

Contact Us
Request a Quote
What's New?
Read Our Newsletter

© Washington Biotechnology Inc., 2014. All Rights Reserved.
Built by Biz-Zone